Log in using OpenID

Alveolar Rhabdomyosarcoma Treatment Market

Alveolar Rhabdomyosarcoma Treatment Market
- Size, Share, Growth, Outlook, and
Opportunity Analysis, 2018-2026
Alveolar rhabdomyosarcoma (ARMS) is a type of soft tissue sarcoma that originates from the
connective tissues of the body such as bone, muscle, cartilage, and ligaments. According to the
survey by Children’s Oncology Group, 2011, alveolar rhabdomyosarcoma makes up about 25-40% of
RMS. ARMS is mostly detected in adolescents and often occurs on the arms, legs, chest, and
stomach. The exact cause of alveolar rhabdomyosarcoma is unknown, however it is associated with
other conditions such as Neurofibromatosis type 1, Beckwith-Wiedemann syndrome, Li-Fraumeni
syndrome, Cardio-facio-cutaneous syndrome, and Costello syndrome. The methods for diagnosis of
ARMS include examination such as X-ray imaging, CT scan, MRI, bone scan, ultrasound, PET scan,
and a biopsy, in order to plan a suitable treatment for the condition. ARMS is a type of high-grade
tumor meaning it cells are characterized by rapid growth and faster progression.
Request Sample Copy of Research Report:
According to the Surveillance, Epidemiology, and End Results (SEER) database, ARMS constitutes
23% of patients among the types of RMS. Also, alveolar rhabdomyosarcoma needs more-intensive
therapy than embryonal rhabdomyosarcoma. Radiation therapy including intensity-modulated
radiotherapy (IMRT) and proton beam radiation therapy are implemented as an effective way to
shrink the tumor cells post chemotherapy. Mostly, chemotherapy and radiation therapy is used to
shrink the size of the tumor before surgery and to minimize the risk of cancer reoccurrence postsurgery.
Alveolar Rhabdomyosarcoma Treatment Market: Market Dynamics
Rising incidence of alveolar rhabdomyosarcoma along with technological advancements in
radiation therapy is expected to augment market growth of alveolar rhabdomyosarcoma
treatment. According to the survey by the University of Minnesota, 2014, soft tissue sarcomas
(STS) comprises about 7% of all malignancies in children and adolescents under the age of 20
years and rhabdomyosarcoma (RMS) accounts for about 40% of pediatric STS. The incidence of
RMS is 4.5 cases/million children/adolescents per year, where ARMS comprises 31% of RMS and
in 50% cases the condition is highly prevalent below the age of 10. Also, latest advancements in
radiation therapy, which are largely adopted by major hospitals such as Mayo Clinic, Memorial
Sloan Kettering Cancer Center include proton beam therapy program that provides highly
targeted precision beams to destroy cancerous cells by sparing the healthy surrounding tissues.
Report includes chapters which deeply display the following deliverable about industry :
• Alveolar Rhabdomyosarcoma Treatment Market Research Objective and Assumption
• Alveolar Rhabdomyosarcoma Treatment Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Alveolar Rhabdomyosarcoma Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Alveolar Rhabdomyosarcoma Treatment Market, By Regions
• Alveolar Rhabdomyosarcoma Treatment Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Alveolar Rhabdomyosarcoma Treatment Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Alveolar Rhabdomyosarcoma Treatment Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Alveolar Rhabdomyosarcoma Treatment Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Alveolar Rhabdomyosarcoma Treatment Market: Competitive Analysis
Key players operating in the global alveolar rhabdomyosarcoma treatment market
include Eli Lilly and Company, GlaxoSmithKline Plc., Boehringer Ingelheim GmbH,
Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Oasmia Pharmaceutical, Celgene
Corporation, Pfizer, Inc., and Johnson & Johnson Services, Inc.
Inquire Here Before Purchase:
Alveolar Rhabdomyosarcoma Treatment Market: Market Taxonomy
On the basis of therapy type, the global alveolar rhabdomyosarcoma treatment market is
segmented into:
• Chemotherapy
• Radiation Therapy
• Combination Therapy
On the basis of end user, the global alveolar rhabdomyosarcoma treatment market is segmented
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
38   documents Email
Health and Medicine
File Size
155 KB
Report inappropriate content